Ghost Tree Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Ghost Tree Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-50,000	Closed	-$1.27M	–	52
2020 Q2	$1.27M	Sell	50,000 -62,695	-56%	-$1.31M	0.34%	40
2020 Q1	$1.75M	Sell	112,695 -237,305	-68%	-$3.71M	0.46%	39
2019 Q4	$3.87M	Buy	+350,000	New	+$3.04M	0.74%	38

Other funds holding KNSA

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ghost Tree Capital's KNSA Position: Q3 2020 in Review

Ghost Tree Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2020, closing a stake of 50,000 shares — an estimated $1.27M sold.

Ghost Tree Capital first reported a position in KNSA in Q4 2019 and held it in 3 quarters. The position peaked at $3.87M in Q4 2019. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2020.

Ghost Tree Capital reported no remaining Kiniksa Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Ghost Tree Capital sold 50,000 Kiniksa Pharmaceuticals shares in Q3 2020, an estimated $1.27M.
Ghost Tree Capital first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Ghost Tree Capital's Kiniksa Pharmaceuticals position peaked at $3.87M in Q4 2019.
104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2020.

Based on Ghost Tree Capital's 13F filing for Q3 2020, filed 16 Nov 2020.